Courses

This CE program will analyze optimal therapeutics for the treatment and management of prostate cancer patients, incorporating data presented at the American Society of Clinical Oncology 2018 Genitourinary (GU) Cancers Symposium in San Francisco, California. The three expert faculty, led by Dr. Elisabeth Heath, will review the framework for clinical decision making in prostate cancer. Recent clinical trial data for ...
View Course

This CME/CE program will delve into the role of oncolytic viral therapy in the treatment and management of the metastatic melanoma patients, highlighting data presented at the Maui and Hawaii Dermatology 2018 annual meetings. The three expert faculty will review the immunotherapy for melanoma, followed by a discussion of recent safety and efficacy trial data for this emerging therapeutic option ...
View Course

This CME/CNE program will highlight recent advances in the treatment and management of breast cancer, as presented at the 40^th Annual San Antonio Breast Cancer Symposium in San Antonio, Texas. Three expert faculty will review the pathophysiology of breast cancer and the rationale for therapeutic choices. An evaluation of recent clinical trial data of current and emerging therapies will be ...
View Course

This educational program will explore and analyze data for PCSK9 inhibitor therapeutics in specific patient populations. Expert faculty will relay updates regarding recent PCSK9 inhibitor data and dive into how to optimally apply these therapies into clinical practice. Recent dyslipidemia guidelines will also be reviewed. The panel will discuss how to best improve outcomes for dyslipidemia patients, including those with stroke or at ...
View Course

The content for this activity is derived from a live symposium titled, “The Important Role of Lipoprotein(a) in Cardiovascular Disease: Present and Future Therapeutic Options” presented at the American Heart Association Scientific Sessions 2017 in Anaheim, California. This CME activity will focus on the role of lipoprotein(a) and its therapeutic options for patients with cardiovascular disease. A review of the ...
View Course

This content is derived from a CME symposium held in conjunction with the Advanced Curriculum for Multiple Sclerosis 2018 in San Diego, California. The five expert faculty will highlight individualized therapeutic strategies of switching and sequencing to improve outcomes for patients with multiple sclerosis (MS). Methods for predicating and monitoring disease therapy in the MS patient population will be reviewed ...
View Course

This CME/CNE program will discuss recent advances in the treatment and management of multiple myeloma (MM) as presented at the American Society of Hematology 59^th Annual Meeting & Exposition in Atlanta, Georgia. The expert faculty panel will provide learners with a scientific update regarding kidney toxicity, fractures, and other skeletal related events as they relate to MM patient care. Recent ...
View Course

This educational activity will feature content presented at the MS Paris 2017 7th Joint ECTRIMS-ACTRIMS Meeting in Paris, France. Four expert faculty will examine recent prognosis and diagnostic strategies of multiple sclerosis. An analysis of clinical trial data of current and emerging disease modifying therapies as presented at the Joint ACTRIMS-ECTRIMS meeting will be discussed. The faculty will also review ...
View Course

This CE program will highlight recent scientific advances in the treatment and management of patients with polycythemia vera (PV) presented at the American Society of Hematology 59^th Annual Meeting & Exposition in Atlanta, Georgia. The three expert faculty will review the science and diagnostic criteria of PV, focusing on the treatment of the resistant/intolerant patient population. Recent clinical trial data, ...
View Course

In this module of a Four-Part Expert Interview Series, Dr. Marc E. Agronin, along with Dr. Richard S. Isaacson, course chair, will evaluate available therapeutic options for Alzheimer’s disease (AD) patient. The faculty will highlight the evolution of failed and existing therapies in AD, and their impact on current clinical care, emphasizing strategies for delaying disease progression in the modern ...
View Course